Paz José A, Silva Clovis A A, Marques-Dias Maria J
Neuropediatrics Unit, Instituto da Criança/Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.
Pediatr Neurol. 2006 Apr;34(4):264-9. doi: 10.1016/j.pediatrneurol.2005.08.028.
In this randomized, double-blind, parallel study of a group of 22 children and teenagers, prednisone efficacy in acute Sydenham's chorea was assessed. Use of prednisone (2 mg/kg/day during 4 weeks, followed by a gradual discontinuation) in the 22 patients and in a placebo group (n = 15) was evaluated by a chorea intensity score based on presence, distribution, and interference of choreic movement on daily activities. Each patient was evaluated by the same pediatric neurologist weekly during the first month, followed by evaluation on weeks 8 and 12, with further evaluations as necessary if choreic movements persisted. Although initial chorea intensity was similar in both groups, a significant difference was observed after 1 week of medication (P < 0.001) with a larger reduction in the prednisone group, that continued until the end of the study. Percentage decrease in chorea intensity scale score also was persistently and significantly (P < 0.001) greater in the prednisone group. Chorea complete remission time with prednisone (mean 54.3 days) was significantly shorter (P < 0.001) when compared with the placebo group (mean 119.9 days). Seven patients presented recurrences, with no difference between groups (13.6% and 26.7% in the prednisone and placebo groups, respectively). Severe adverse events to prednisone were not observed.
在这项针对22名儿童和青少年的随机、双盲、平行研究中,评估了泼尼松对急性风湿性舞蹈病的疗效。根据舞蹈样动作的存在、分布以及对日常活动的干扰情况,通过舞蹈病强度评分来评估22例患者以及一个安慰剂组(n = 15)使用泼尼松(4周内每日2 mg/kg,随后逐渐停药)的效果。在第一个月内,每周由同一位儿科神经科医生对每位患者进行评估,随后在第8周和第12周进行评估,如果舞蹈样动作持续存在,则根据需要进行进一步评估。尽管两组初始舞蹈病强度相似,但用药1周后观察到显著差异(P < 0.001),泼尼松组的舞蹈病强度降低幅度更大,这种差异一直持续到研究结束。泼尼松组舞蹈病强度量表评分的降低百分比也一直显著更高(P < 0.001)。与安慰剂组(平均119.9天)相比,泼尼松组舞蹈病完全缓解时间(平均54.3天)显著更短(P < 0.001)。7例患者出现复发,两组之间无差异(泼尼松组和安慰剂组分别为13.6%和26.7%)。未观察到泼尼松的严重不良事件。